These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 6452200)

  • 1. Phase I study of GANU and MCNU.
    Ogawa M
    Cancer Treat Rev; 1980 Dec; 7(4):197-203. PubMed ID: 6452200
    [No Abstract]   [Full Text] [Related]  

  • 2. Current status of nitrosoureas under development in Japan.
    Ogawa M; Fujimoto S
    Recent Results Cancer Res; 1981; 76():115-24. PubMed ID: 6453413
    [No Abstract]   [Full Text] [Related]  

  • 3. Antitumor effects of GANU and other nitrosourea derivatives against transplantable leukemias and solid tumors in mice.
    Sava G; Giraldi T
    Cancer Chemother Pharmacol; 1983; 10(3):167-9. PubMed ID: 6222844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Phase II study of 3 new nitrosoureas, 1 American (chlorozotocin) and 2 French (RFCNU and RPCNU)].
    Mathé G; Schein PS; De Vassal F; Serrou B; Imbach JL
    Sem Hop; 1982 Sep; 58(33):1867-71. PubMed ID: 6293062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological and biochemical properties of 1-(2-chloroethyl)-3-(beta-D-glucopyranosyl)-1-nitrosourea (NSC D 254157), a nitrosourea with reduced bone marrow toxicity.
    Fox PA; Panasci LC; Schein PS
    Cancer Res; 1977 Mar; 37(3):783-7. PubMed ID: 138478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II evaluation of chlorozotocin (NSC-178248) in advanced human cancer.
    Talley RW; Samson MK; Brownlee RW; Samhouri AM; Fraile RJ; Baker LH
    Eur J Cancer (1965); 1981 Mar; 17(3):337-43. PubMed ID: 6455296
    [No Abstract]   [Full Text] [Related]  

  • 7. [Comparative effect of administration schedules on the antitumor activities of 3 water-soluble nitrosoureas, ACNU, GANU and MCNU against L1210 leukemia].
    Kato T; Ota K
    Gan To Kagaku Ryoho; 1983 May; 10(5):1354-62. PubMed ID: 6223585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 3-(Tetraacetyl glucopyranos-2-yl)-1-(2-chloroethyl)-1-nitrosourea, an antitumor agent with modified bone marrow toxicity.
    Schein PS; McMenamin MG; Anderson T
    Cancer Res; 1973 Sep; 33(9):2005-9. PubMed ID: 4353476
    [No Abstract]   [Full Text] [Related]  

  • 9. [Experimental studies on oral administration of nitrosourea anti-tumor agent, MCNU].
    Sekido S; Ninomiya K; Araki T; Ueno M; Kinbara M
    Gan To Kagaku Ryoho; 1984 Jul; 11(7):1492-500. PubMed ID: 6234861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of derivatives of Ara-C, 5-fluorouracil and nitrosourea against intracerebral implanted L1210 leukemia].
    Kato T; Ota K
    Gan To Kagaku Ryoho; 1987 Feb; 14(2):502-5. PubMed ID: 2949703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of experimental studies on nitrosourea derivatives in Japan.
    Tsukagoshi S
    Recent Results Cancer Res; 1980; 70():107-17. PubMed ID: 7355242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial with chlorozotocin in advanced colorectal cancer.
    Bleiberg H; Rozencweig M; Michel J; Clavel M; Longeval E; Feremans W; Bondue H; Lardinois J; Crespeigne N; Kenis Y
    Eur J Cancer Clin Oncol; 1981 Aug; 17(8):863-6. PubMed ID: 6459936
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of the experimental antitumor activities of three nitrosourea derivatives chlorozotocin, RFCNU and CNCC encapsulated in liposomes with those in the free state.
    Maral R; Bourut C; Chenu E; Mathe G; Bernon R; Lussan C; Imbach JL; Schein P; Bothorel P
    Oncology; 1985; 42(2):122-8. PubMed ID: 3157909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical trial of MCNU for malignant brain tumors].
    Harada K; Okamoto H; Fujioka Y; Uozumi T; Kiya K; Kitaoka T; Goishi A; Sasaki U; Shima T; Inagawa T
    Gan To Kagaku Ryoho; 1985 Jul; 12(7):1423-31. PubMed ID: 2990350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The nitrosoureas and pulmonary toxicity.
    Weiss RB; Poster DS; Penta JS
    Cancer Treat Rev; 1981 Jun; 8(2):111-25. PubMed ID: 6454489
    [No Abstract]   [Full Text] [Related]  

  • 16. [Phase II study of methyl 6-[3-(2-chloroethyl)-3-nitrosoureido]-6-deoxy-alpha-D-glucopyranoside (MCNU)].
    Tanaka I; Kobayashi T; Shirakawa S; Ikeda Y; Kobayashi M; Yamagata K; Ohta K; Ohno R; Yamada H; Yamada K
    Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):493-8. PubMed ID: 3859248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II evaluation of chlorozotocin in refractory multiple myeloma.
    Forman WB; Cohen HJ; Bartolucci AA; Manning G
    Cancer Treat Rep; 1984 Nov; 68(11):1409-10. PubMed ID: 6238673
    [No Abstract]   [Full Text] [Related]  

  • 18. PCNU in advanced adenocarcinoma of the ovary: a phase II study.
    Decker DA; Samson MJ; Baker LH
    Cancer Treat Rep; 1983 May; 67(5):511-2. PubMed ID: 6850668
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase II multicentre study of the nitrosourea fotemustine in inoperable squamous cell lung carcinoma.
    Le Chevalier T; Zabbe C; Gouva S; Cerrina ML; Quoix E; Riviere A; Berthaud P; Prache C; Berille J
    Eur J Cancer Clin Oncol; 1989 Nov; 25(11):1651-2. PubMed ID: 2687005
    [No Abstract]   [Full Text] [Related]  

  • 20. A new nitrosourea derivative for the treatment of chronic myelogenous leukemia.
    Hiraoka A; Masaoka T; Shibata H; Miyazaki T; Nakamura T; Yasunaga K; Kitani T; Yonezawa T; Kawagoe H; Horiuchi A
    Leuk Res; 1988; 12(6):487-90. PubMed ID: 3043111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.